Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode! 🧬💊 ICOTYDE: THE BREAKTHROUGH ORAL PEPTIDE TAKING ON ARTHRITIS - NO INJECTIONS REQUIRED! Could a simple daily pill change the future of peptide medicine and inflammatory arthritis treatment? A groundbreaking oral peptide called ICOTYDE (icotrokinra) is making headlines! Already FDA-approved for certain patients with plaque psoriasis, this innovative medication is now showing promising Phase 3 clinical trial results for psoriatic arthritis. And here’s what makes it so exciting… It’s a peptide you SWALLOW instead of inject! In this episode of The Peptide Effect, we’re diving into the science behind ICOTYDE, how it targets inflammation, and why this development could open the door to an entirely new generation of oral peptide medications. 🔬 What we’re covering: 💊 No injections required! How scientists engineered a peptide that can be taken orally. 🧬 The science of ICOTYDE: How blocking the IL-23 receptor helps regulate inflammatory signaling. 🔥 Arthritis and inflammation: Understanding psoriasis, psoriatic arthritis, and the immune system. 📊 The latest clinical trial results: Why 58% of ICOTYDE patients achieved an ACR20 response compared with 41% receiving placebo. 💪 Joint pain and mobility: What the research reveals about improving symptoms and physical function. ✨ Skin improvements: How ICOTYDE is helping patients with moderate to severe plaque psoriasis. ⚠️ Side effects and safety: What researchers know and what questions remain. 🔮 The future of oral peptides: Could this technology transform how other peptide medications are developed? Is ICOTYDE the beginning of a new era in peptide medicine? We’re breaking down the clinical evidence, separating scientific breakthroughs from marketing hype, and exploring why this medication is generating excitement in both dermatology and rheumatology. 🎙️ Whether you’re interested in peptide science, autoimmune diseases, inflammation, arthritis research, or the future of medicine, this is an episode you won’t want to miss! ⚠️ Medical Disclaimer: This podcast is for educational purposes only and does not constitute medical advice. ICOTYDE is FDA-approved for certain patients with plaque psoriasis, but its use for psoriatic arthritis remains investigational. Always consult a qualified healthcare professional before making treatment decisions. 🎧 The Peptide Effect Thanks for listening, keep learning and stay curious! #ThePeptideEffect #ICOTYDE #Icotrokinra #PeptideScience #OralPeptides #PsoriaticArthritis #Psoriasis #ArthritisResearch #Inflammation #IL23 #AutoimmuneDisease #PeptideNews #MedicalBreakthroughs #JohnsonAndJohnson #FutureOfMedicine
Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.
Transcript
From the show. Tap a time to play from there.
Welcome back to The Peptide Effect, where we explore the science, research, and rapidly evolving world of peptides. Before we begin, here's our medical disclaimer. This podcast is intended for educational and informational purposes only. Nothing discussed in this episode should be considered medical advice, a recommendation to use any medication or experimental treatment, or a substitute for guidance from a qualified healthcare professional. The medication discussed today has received FDA
approval for certain forms of Plaxoriasis, but its use for psoriatic arthritis remains investigational. All medications have potential risks, side effects, and limitations. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment. Now let's talk about something that could represent a major breakthrough in peptide medicine. Imagine treating a chronic inflammatory condition with a peptide. But instead of injecting it, you simply swallow a pill. No
needles. No mixing powders. No reconstituting vials. Just an oral medication designed to target a specific part of the immune system. And here's where things get especially interesting. This isn't some experimental peptide being promoted by an online research chemical company. We're talking about an actual pharmaceutical medication that has already received FDA approval for treating moderate to severe plaque psoriasis. And now, new Phase 3 clinical trial results suggest that it could potentially help people living with
psoriatic arthritis. The medication is called Icotrokinra. It's marketed under the brand name Icotide, pronounced I -co -tide, and it is being developed by Johnson & Johnson. On November 7, 2026, the company announced results from a Phase 3 clinical trial investigating Icotide in adults with active psoriatic arthritis. The study demonstrated significant improvements in joint symptoms compared with placebo. And in patients who also had substantial psoriasis involvement, the medication produced
impressive improvements in skin symptoms. But what makes this story particularly fascinating isn't just the clinical trial results. It's the technology behind the medication. Because icotide is a peptide. A 13 -amino acid peptide, to be exact. And unlike most of the peptide medications we've discussed on this podcast, this one is taken orally. That raises some very interesting questions. How can a peptide survive the digestive system? How does it influence inflammation? Could
it eventually replace some injectable arthritis medications? And does its success mean that we're entering a new generation of oral peptide treatments? Today, we're going to explore all of those questions. We'll break down what psoriatic arthritis actually is, how the immune system contributes to the disease, how Iketide works, and what the newest clinical trial results reveal. We'll also discuss the potential side effects, what researchers still need to learn, and why this development could extend far beyond dermatology and rheumatology.
Because the science behind this medication may be just as important as the condition it's designed to treat. To understand why eichotide matters. We first need to understand the disease. Let's begin with psoriasis. Many people recognize psoriasis as a skin condition. They associate it with red, irritated patches of skin covered by thick, silvery scales. And while those symptoms are common, psoriasis is much more complicated than dry or irritated skin. Psoriasis is a chronic immune
-mediated inflammatory disease. That means the immune system plays a central role in producing the condition. Normally, your immune system protects your body against threats such as bacteria, viruses, and other potentially harmful substances. It coordinates immune cells, releases chemical signals, and activates inflammatory responses when necessary. Inflammation is not automatically a bad thing. In fact, inflammation is an essential part of normal immune function. If you cut your finger,
Inflammatory signaling helps recruit cells involved in protecting and repairing the injured tissue. If you develop an infection, inflammation helps coordinate your body's response. The problem occurs when those inflammatory processes become excessive, inappropriate, or persist longer than they should. In psoriasis, certain immune pathways become overactive. These pathways communicate with skin cells and influence how quickly those cells grow and mature. Normally, skin cells develop,
move toward the surface, and are eventually shed through a regulated process. But in psoriasis, inflammatory signals can accelerate skin cell production. The cells accumulate faster than they are shed. And that contributes to the characteristic thicken plaques. The inflammation can also produce redness, itching, irritation, and discomfort. For some people, psoriasis affects relatively small areas. For others, it can involve large portions of the body, and certain locations can
be particularly difficult. Imagine having painful plaques on your hands. Every time you wash dishes, open a package, or perform an ordinary task, those areas may become irritated. Or imagine psoriasis affecting your scalp. The itching, flaking, and discomfort can interfere with sleep and daily activities. Psoriasis can also affect the genital area, feet, nails and other sensitive locations. And because the condition is visible,
many people experience emotional distress or social embarrassment. Some avoid certain clothing. Others become uncomfortable with physical contact. And some struggle with the unpredictability of their symptoms. But there's another important part of this disease. For a substantial number of people with psoriasis, inflammation doesn't remain limited to the skin. It can also affect the joints. And that brings us to psoriatic arthritis. Psoriatic arthritis is a chronic inflammatory disease that can cause joint pain, stiffness,
swelling, and tenderness. It can affect the fingers, toes, wrists, knees, spine, and other parts of the musculoskeletal system. Some people experience swelling of an entire finger or toe. This is called dactylitis. It's sometimes described as a sausage digit because the entire finger or toe becomes swollen. Others develop inflammation where tendons and ligaments attach to bones. That condition is called enthesitis. And for some patients, the disease affects the spine
or sacroiliac joints, causing back pain and stiffness. Now here's something important. Psoriatic arthritis is not the same thing as osteoarthritis. Osteoarthritis involves changes in joint tissues that can result from multiple factors, including age, mechanical stress, previous injuries, and biological processes. Psoriatic arthritis, on the other hand, is an immune -mediated inflammatory condition. The immune system contributes directly to inflammation in and around the joints. And if that inflammation
remains uncontrolled, some patients can experience progressive joint damage. This is why treating psoriatic arthritis involves more than simply making pain temporarily disappear. The goal is to reduce disease activity, preserve joint function, prevent complications, and improve quality of life. And that can be challenging. Symptoms vary significantly between patients. One person may have relatively mild joint involvement with extensive skin psoriasis. Another may have severe joint
symptoms but relatively little visible skin disease. Some experience inflammation in only a few joints. Others experience widespread involvement. And symptoms may change over time. There can be periods of improvement followed by flare -ups. According to research cited by Johnson & Johnson, nearly 30 % of people with plaque psoriasis may develop psoriatic arthritis. That doesn't mean everyone with psoriasis will develop joint disease. But it demonstrates why clinicians take joint symptoms
seriously in patients with psoriasis. Early recognition and appropriate treatment can be important for protecting long -term joint health. Now, let's move into the biology. Because this is where Iketide becomes particularly interesting, the medication targets a signaling pathway involving a molecule called interleukin -23, usually abbreviated IL -23. Interleukins are proteins that help immune cells communicate. They're part of a larger family of signaling molecules called cytokines. You
can think of cytokines as messages passing between cells. Some messages tell immune cells to become more active. Others help regulate immune responses. And still others influence inflammation, tissue repair, and cellular behavior. Interleukin -23 plays an important role in the development and maintenance of certain inflammatory immune responses. It's particularly associated with a group of immune cells called T -helper -17 cells. These cells participate in immune defense. But when
their signaling becomes dysregulated, they can contribute to inflammatory diseases. Interleukin -23 helps support pathways involving inflammatory molecules such as interleukin -17. And those pathways are important in the development of psoriasis and psoriatic disease. Now, imagine an inflammatory communication system that keeps sending messages telling immune cells to remain active. Those messages contribute to inflammation in the skin. And in some patients, inflammation
affecting the joints and surrounding tissues. One strategy for treating these conditions is to interrupt the communication pathway. And that's exactly what several modern immune targeting medications are designed to do. But different medications interrupt the pathway in different ways. Some drugs target interleukin -23 itself. Others target interleukin -17. And some target additional components involved in immune signaling. Iketide takes a particularly interesting approach.
Instead of directly binding to interleukin -23, it binds to the interleukin -23 receptor. That's an important distinction. The receptor is the structure that receives the signal. Think of interleukin -23 as a message. And think of its receptor as the receiving station. Under normal circumstances, interleukin -23 interacts with its receptor and triggers biological signaling. Iketide is designed to interfere with that interaction. By binding to the receptor, the medication prevents
interleukin -23 from activating its normal signaling pathway. The result is reduced activity within an inflammatory pathway associated with psoriasis. This is why eichotide is classified as an interleukin -23 receptor antagonist. An antagonist blocks or interferes with receptor activation. And in this case, the goal is to reduce inappropriate inflammatory signaling. Now let's talk about why this is such an interesting achievement in peptide chemistry. because many peptides are
extremely difficult to develop as oral medications. We've discussed this before on the peptide effect. Peptides are made from chains of amino acids. Amino acids are the building blocks used to construct proteins and peptides. But when you swallow a peptide, it enters a digestive system designed to break down proteins. The stomach and intestines contain enzymes that help dismantle proteins and peptides into smaller components. These enzymes are essential for normal digestion, but they
create a major challenge for researchers developing peptide medications. If a peptide is broken apart before it reaches its intended target, it may never produce the desired therapeutic effect. And even if it survives digestion, it still has to cross biological barriers. The intestinal lining is selective about what enters the bloodstream. Many peptides are relatively large and have chemical properties that make absorption difficult. That's one reason so many peptide medications are administered
through injections. Injecting a medication can bypass some of the barriers associated with the gastrointestinal tract. But injections come with their own challenges. Some patients dislike needles. Others struggle with self -administration. Some medications require special storage. and repeated injections can become inconvenient. So, pharmaceutical researchers have spent decades investigating how to deliver peptides orally. The challenge isn't simply putting a peptide into a capsule.
The challenge is designing a molecule and formulation that can survive long enough, reach the body in sufficient quantities, and produce a predictable therapeutic effect. Icatide represents an important accomplishment in that area. It is a 13 -amino acid peptide specifically engineered to interact with the interleukin -23 receptor, and its formulation allows it to be administered as a once -daily oral tablet. Now, here's an important detail. Just because a peptide can be administered orally
doesn't mean food has no effect on its absorption. In fact, Iketide's prescribing information specifically addresses this issue. The approved medication is taken on an empty stomach with water upon waking. Patients are instructed to wait at least 30 minutes before eating. That timing is important because food can significantly affect the amount of medication absorbed. In pharmacokinetic research, administering Icatide with a high -fat meal reduced total drug exposure by approximately 43%. The
peak concentration was reduced by approximately 59%. That's a substantial difference. And it demonstrates why the formulation and administration instructions matter. The goal isn't simply getting a peptide into the stomach. It's getting enough of the intact medication into the body to interact with its target. Now, let's move to the clinical history. Because eichotide didn't suddenly appear in November of 2026. The medication was already being investigated for several years. Researchers
initially focused heavily on plaque psoriasis. That made sense because the interleukin -23 pathway has an established role in the disease. Several medications that target related immune pathways have already demonstrated substantial effectiveness in treating psoriasis. The challenge was developing a targeted oral peptide capable of producing meaningful results. Johnson and Johnson conducted multiple clinical trials through a research program known as ICONiC. These studies evaluated eikatide
in adults and adolescents with moderate to severe plaque psoriasis. Some trials compared it with placebo. Others included comparisons with existing medications, and researchers measured outcomes involving the severity and extent of skin disease. One commonly used measurement is called the psoriasis area and severity index, usually abbreviated PASI. This measurement considers several features of psoriasis, including the area of the body affected, the redness of lesions, the thickness
of plaques, and the degree of scaling. Researchers often report something called PASI90. That means a patient experienced at least a 90 % improvement from their original psoriasis severity score. Now, a 90 % improvement doesn't necessarily mean every single lesion has completely disappeared, but it represents a substantial reduction in disease severity. Another measurement is the investigator's global assessment. This evaluates overall skin disease severity. A score of zero
generally represents clear skin, and a score of one represents almost clear or minimal disease. When researchers report that patients achieved an investigator's global assessment score of zero or one, they're describing people whose skin was considered clear or nearly clear under the study's evaluation system. These measurements became central to the clinical research supporting eichotide, and the results were significant enough to support an FDA approval application. On March 17, 2026, the FDA approved Iketide for moderate
to severe plaque psoriasis. The approval includes adults and adolescents 12 years of age and older who weigh at least 40 kilograms or approximately 88 pounds. These patients must also be candidates for systemic therapy or phototherapy. Systemic therapy refers to treatment that acts throughout the body rather than only at the surface of the skin. Phototherapy uses controlled exposure to specific wavelengths of ultraviolet light. So, Eichatide was approved for a defined patient
population with clinically significant plaque psoriasis. The FDA reviewed evidence from four clinical trials involving approximately 2 ,500 participants. These studies were conducted across hundreds of research locations in multiple countries. And that brings us to a key distinction. Iketide is not simply a peptide with promising laboratory research. It is an FDA -approved medication for plaque psoriasis. But that approval does not automatically extend to every condition involving
inflammation. And it does not mean the medication is approved for all types of arthritis. Its use for psoriatic arthritis is still being investigated. Now let's discuss the new results that brought this medication back into the headlines. On November 7, 2026, Johnson and Johnson announced positive findings from a phase 3 trial called ICONiC PSA1. This study specifically investigated eichotide in adults with active psoriatic arthritis. The participants were biologic naive. That means
they had not previously received biologic therapies for their condition. This distinction matters because patients who have already tried multiple advanced treatments may respond differently from those who have never received them. The study used a randomized, double -blind, placebo -controlled design. And that's important. Randomization helps reduce differences between treatment groups. Double -blinding means neither participants nor investigators know which assigned treatment a participant is receiving during the blinded comparison
period, and the placebo group allows researchers to measure whether the medication produces greater improvements than would be observed without the active treatment. The trial enrolled approximately 550 adults. Researchers evaluated a once -daily 200mg oral dose of Iketide. And they focused on a measurement called ACR20. ACR stands for the American College of Rheumatology. ACR20 is a composite measure used in clinical trials involving
inflammatory arthritis. To achieve an ACR20 response, patients must demonstrate at least a 20 % improvement in both tender and swollen joint counts. They must also meet improvement criteria involving other measurements of disease activity. These can include assessments of pain, physical function, and overall disease severity. Now, here's something important. An ACR20 response does not mean arthritis has been cured. It does not mean every patient's pain decreased by exactly 20 % and it does not
mean joint damage has been reversed. It is a standardized research measurement indicating improvement across several aspects of inflammatory arthritis. Researchers also evaluate ACR50 and ACR70. Those represent progressively higher improvement thresholds and they can help determine how many patients experience larger clinical responses. Now let's look at what happened. At week 16, 58 % of patients receiving Iketide achieved an ACR20 response, compared with 41 % receiving
placebo. That's a 17 percentage point difference, and the trial met its primary endpoint. This means the study demonstrated a statistically significant improvement in its main pre -specified measurement. But I want to emphasize something. 41 % of the placebo group also achieved an ACR20 response. That is not unusual in trials involving subjective symptoms, fluctuating inflammatory diseases, and complex outcome measurements. People
may improve because of natural variation in disease activity, background treatments, expectations, or other factors. That's precisely why placebo -controlled trials are so important. They help researchers determine how much additional benefit can reasonably be attributed to the medication. In this trial, the proportion achieving ACR20 was meaningfully higher with icotide. Now let's examine the more demanding measurements. At week 16, 29 % of patients receiving icotide achieved
an ACR50 response, compared with 16 % receiving placebo. For ACR70, 13 % of patients receiving Iketide met the threshold, compared with 5 % receiving placebo. These results suggest that some patients experienced substantial improvement in inflammatory arthritis activity. However, the higher response thresholds were achieved by smaller proportions of patients, and that is an important part of evaluating effectiveness.
A treatment can produce meaningful improvement without putting every patient into remission. And while the results are encouraging, they also show that many participants did not reach the more demanding response targets. Now, here's where the findings become especially interesting. The researchers didn't only evaluate joints. They also examined skin symptoms. Remember, psoriatic arthritis can involve both joint inflammation and plaque psoriasis. And treating both components effectively can be challenging. Among participants
with qualifying skin involvement, 57 % receiving eikatide achieved clear or almost clear skin at week 16. Compared with 14 % receiving placebo, that's a very substantial difference. And when researchers evaluated PAS -I90, 37 % receiving eikatide achieved at least a 90 % improvement in their psoriasis severity score. Compared with 6 % receiving placebo, So, the medication demonstrated
benefits involving both joint disease and skin involvement. That dual effect is particularly important because some people with psoriatic arthritis require treatment strategies addressing several different disease manifestations. A medication that helps control both skin and joint symptoms could potentially offer meaningful advantages for certain patients. But it is also important to recognize that psoriatic arthritis is not a single symptom disease. Patients may experience enthesitis, dactylitis, spinal symptoms, fatigue,
and functional limitations. A complete understanding of a treatment's effectiveness requires examining those different aspects of the disease. The headline results tell us something important, but they don't tell us everything. Now, let's look at what happened after week 16. The trial continued evaluating patients through week 24. and the response rates among IKITI -treated patients continued to increase numerically. By week 24, 69 % had achieved an ACR20 response, 40 % achieved
ACR50, and 18 % achieved ACR70. Among participants with qualifying skin involvement, 64 % achieved clear or almost clear skin, and 56 % achieved PASI90. These results suggest that some patients may experience additional improvement with continued treatment. However, we need to be careful when interpreting the later results. At week 16, participants receiving placebo crossed over to active treatment.
That means the week 24 data should not be interpreted as a simple continuation of the original placebo comparison. Without maintaining the same untreated comparison group, it becomes more difficult to draw the same type of conclusions about treatment differences. Still, the reported response patterns provide useful information about how outcomes evolved during treatment. And the findings add to the larger body of research investigating this medication. Now let's talk about safety. Because any medication that changes immune signaling
deserves careful evaluation. The immune system is an incredibly complex network. and targeting one inflammatory pathway can influence more than the symptoms researchers are trying to control. Interleukin -23 participates in immune defense. It is involved in biological processes that help the body respond to certain infections. So, interfering with that signaling pathway can potentially affect infection risk. This is not unique to Iketide. Many medications used for inflammatory and autoimmune
conditions affect immune function. The goal is to reduce inappropriate inflammation while preserving enough immune activity to protect the body. But that balance is not always simple. According to the FDA -approved prescribing information for Iquatide, clinicians should consider the possibility of infections. Treatment should be avoided in patients with clinically important active infections until those infections resolve or are adequately treated. The prescribing information also addresses tuberculosis. Clinicians may consider
evaluating patients for tuberculosis before starting treatment based on medical judgment. And patients should be monitored for signs or symptoms of active tuberculosis during and after treatment. Vaccinations are another consideration. The prescribing information recommends completing age -appropriate immunizations according to current guidelines. And live vaccines should be avoided during eichatide treatment. Now, what about the side effects observed in the clinical trials? In the psoriasis studies supporting FDA approval, the most commonly reported
adverse reactions included headache, nausea, cough, fungal infections, and fatigue. For example, headache was reported in approximately 4 % of patients receiving Iketide during the initial 16 -week placebo -controlled period, compared with approximately 3 % receiving placebo. Nausea occurred in a little over 1 % of the Iketide group. Fungal infections were also reported in slightly more than 1%. These percentages may sound relatively small, but individual experiences
can vary. And uncommon adverse effects may become more apparent when a medication is used by larger populations over longer periods. The prescribing information also includes precautions involving pregnancy and kidney impairment. For patients with moderate or severe kidney impairment, Additional monitoring for potential adverse reactions is recommended. In the new psoriatic arthritis trial, Johnson and Johnson reported that safety findings through week 24 were consistent with the medication's established safety profile. No new safety signals
were identified. That's encouraging. But no new safety signals does not mean no safety risks. And it doesn't mean long -term safety has been completely established for every patient population. Continued monitoring remains important. Now, here's another interesting development. In August of 2026, researchers published a pooled safety analysis involving approximately 2 ,400 patients who received eichotide in psoriasis studies. The analysis included information extending through
one year of treatment. Researchers reported that adverse event rates during the initial placebo -controlled period were generally comparable between eichotide and placebo. and the overall safety findings remained consistent through the longer observation period. That's valuable information because one of the major concerns with any immune targeting therapy is what happens after repeated exposure over time. Short -term trials can identify common adverse reactions, but longer follow -up is needed to better understand uncommon complications
and sustained tolerability. And in October of 2026, Johnson and Johnson also announced longer -term psoriasis findings extending to approximately two years. The results suggested that substantial skin improvements could be maintained among patients who remained in the study. Again, that's encouraging. But long -term studies must always be interpreted carefully. Patients who remain on treatment may differ from those who discontinue it. And the absence of a newly identified safety signal does
not eliminate the possibility of rare or delayed adverse effects. Now, let's address a question I know some listeners are probably asking. Could Iketide replace injectable biologic medications? The answer is that it may become an important additional option, but it is far too early to say that it will replace them. There are already several effective medications used to treat psoriatic arthritis. Some are injectable biologic therapies, some are oral medications, and some work through different immune pathways. Biologic medications
can be highly effective, but some patients dislike injections. Others find treatment schedules inconvenient and some experience inadequate responses or adverse reactions. An effective oral peptide targeting interleukin 23 receptors could provide another approach, but convenience alone does not establish clinical superiority. A medication has to be evaluated for effectiveness, safety, durability, and its ability to control different manifestations of the disease. And different patients may benefit
from different treatments. Some may need stronger control of joint inflammation. Others may have severe skin involvement. And others may have additional medical conditions that influence medication selection. It's also important to recognize that Icotide is not the first oral medication used for psoriatic disease. Oral treatments already exist. The innovation here is the particular molecular design and mechanism. Iketide is a targeted oral peptide that blocks the interleukin -23 receptor and that represents a distinct approach
to immune targeting therapy. Now let's consider what this development could mean for peptide science more broadly. Because I think this is one of the most exciting parts of a story. For years, Many peptide enthusiasts have focused on compounds associated with growth hormone signaling, tissue repair, metabolism, and longevity. And those areas continue to generate enormous interest. But peptide medicine is much larger than the compounds most frequently discussed online. Researchers are developing peptides that influence immune
signaling, peptides that target specific receptors, peptides designed to deliver therapeutic molecules. and peptides engineered to overcome biological barriers that historically made certain treatments difficult. Iketide demonstrates how sophisticated peptide design has become. We're talking about a molecule containing 13 amino acids. Yet that molecule has been engineered to bind to a highly specific receptor involved in immune function, and it can be delivered orally. That combination
is impressive. Not because all oral peptides will suddenly become possible, but because it demonstrates that researchers can sometimes overcome challenges previously considered extremely difficult. Of course, that doesn't mean you can take any injectable peptide, put it into a capsule, and expect the same results. Different peptides have different chemical structures, different stability characteristics, different absorption properties, and different biological targets. A formulation
that works for one peptide may be completely ineffective for another. Oral bioavailability is extremely compound -specific, and pharmaceutical development requires extensive research to determine whether a particular molecule can be administered successfully. Still, the success of icotide could encourage additional investigation into orally delivered peptides, and that could influence research far beyond inflammatory skin disease. Imagine future peptide medications designed to target specific inflammatory pathways without
requiring injections, or molecules engineered to influence receptors associated with neurological conditions, or oral formulations that provide predictable delivery of therapeutic peptides currently available only through injection. Those possibilities are exciting, but they're possibilities. They're not established outcomes. Each new medication would still need its own clinical development program, and each one would have to demonstrate acceptable safety and effectiveness. Now, let's
return to arthritis for a moment, because I want to address a misconception that could easily develop from the headlines. Icatide is not a general purpose pain medication. It is not designed to function like ibuprofen or acetaminophen. It does not simply block pain signals. Its primary mechanism involves interfering with a specific inflammatory signaling pathway. And that distinction matters. Pain can have many different causes. Nerve damage, mechanical injury, degenerative
joint changes, muscle strain, autoimmune inflammation, and numerous other conditions. A medication targeting interleukin -23 receptors may be useful for certain immune -mediated inflammatory diseases. But that does not establish that it will relieve every form of arthritis, nerve pain, or chronic musculoskeletal discomfort. For example, the current results do not demonstrate that eichotide treats ordinary osteoarthritis. They do not establish its effectiveness
for rheumatoid arthritis. And they do not demonstrate benefits for chronic pain unrelated to the disease being studied. Each condition has its own underlying biology. And the effectiveness of an immune targeting medication depends on whether the relevant pathway actually contributes meaningfully to that disease. This is one reason precision medicine is becoming such an important part of modern healthcare. Instead of treating every inflammatory condition as if it were identical, researchers are identifying
the molecular pathways involved. And they're developing medications designed to target those pathways, more specifically. Now, Some listeners may wonder whether blocking inflammation is always desirable. After all, inflammation is part of normal healing, and the immune system needs to function properly to protect us. That's an excellent question. The objective of immune targeted therapy isn't to eliminate all inflammation. That would be neither practical nor desirable. The objective
is to reduce inappropriate or excessive activity within particular pathways associated with disease. In psoriatic arthritis, immune -mediated inflammation contributes to symptoms and potentially to tissue damage. By reducing that activity, treatment may improve disease control. But the immune system is interconnected. Interfering with one pathway can influence other biological processes. That's why targeted medications still require safety monitoring. And it's why a treatment that works
extremely well for one person may not be appropriate for another. Now, let's talk about what comes next for Iketide. As of November 2026, the medication is approved in the United States for moderate to severe plaques psoriasis in a specified patient population. Its use for active psoriatic arthritis remains investigational. The positive phase III findings provide evidence that may support further regulatory evaluation. But a successful clinical trial does not automatically result in an expanded
FDA approval. Regulators review clinical effectiveness. They review safety information. They examine manufacturing and product quality. And they evaluate whether the evidence supports the proposed indication. Additional data may also be necessary. Johnson & Johnson is continuing its clinical development program. And future results will help determine how this medication may fit into psoriatic arthritis treatment. One particularly important question will be how Iketide compares directly with established
active treatments. Placebo -controlled trials demonstrate whether a medication provides benefit beyond the comparison group. But clinicians also want to know how it performs against other effective therapies. Does it produce similar joint improvement? Does it produce better skin clearance? How do the safety profiles compare? And what happens after years of treatment? Those are the questions that could determine whether this oral peptide becomes a preferred option for certain patients. Another important consideration is treatment access. Even when a medication receives FDA approval,
that doesn't guarantee that every patient can obtain it easily. Insurance coverage can vary. Prior authorization requirements may apply. And medication costs can influence treatment decisions. A once -daily pill may be convenient. But convenience provides limited benefit if patients cannot afford or consistently obtain the medication. So, the real -world impact of Iketide will depend on more than clinical trial results. It will also depend on prescribing practices, insurance decisions,
affordability, long -term safety, and patient experiences. Now, let's revisit the numbers one more time. Because they really are the foundation of this story. In the phase 3 psoriatic arthritis trial, 58 % of patients receiving Iketide achieved an ACR 20 response at 16 weeks, compared with 41 % receiving placebo, 29 % achieved ACR 50, compared with 16 % receiving placebo, and 13 % achieved ACR 70, compared with 5 % receiving
placebo. Among patients with qualifying psoriasis involvement, 57 % achieved clear or almost clear skin, compared with 14 % receiving placebo, and 37 % achieved at least a 90 % improvement in their psoriasis severity score, compared with 6 % receiving placebo. By week 24, the reported ACR20 response among eichatide -treated patients had increased to 69%. These results are promising.
But they're not evidence that every patient will experience substantial improvement. They're not proof that the medication reverses permanent joint damage. And they're not a guarantee that the treatment will eventually receive approval for psoriatic arthritis. They are evidence from a large clinical trial demonstrating clinically meaningful improvements in a specific patient population. And that is an important distinction. because responsible scientific reporting means celebrating progress without exaggerating what
the results prove. Now there's something else that makes this particular peptide stand out. Unlike many experimental compounds discussed in the wellness industry, Iketide has already completed the regulatory process for an approved indication. Its manufacturing is regulated as an FDA approved pharmaceutical product. Its prescribing information contains established dosing and administration instructions. And its safety profile has been evaluated through a substantial clinical development program. That's a very different situation from
purchasing an unapproved research peptide with limited human clinical evidence. The word peptide describes the type of molecule. It does not tell us whether the substance has been adequately studied. And it does not tell us whether the medication is appropriate for treating a particular condition. Icatide is an excellent example of how peptide research can progress from molecular discovery through large clinical trials and ultimately into approved medical treatment. And that journey deserves recognition. Because pharmaceutical
development is difficult. Many promising molecules never reach the market. Some fail because they don't produce enough benefit. Others fail because of unacceptable adverse effects. and some simply cannot be manufactured or delivered reliably enough for practical clinical use. So, developing an oral peptide that selectively targets an immune receptor and demonstrates clinical effectiveness is a meaningful scientific accomplishment. Now, what does all of this mean for the future? I
believe we're seeing continued progress toward more precisely targeted peptide medications. Researchers are becoming increasingly capable of designing molecules that interact with specific biological systems. And they're learning how to modify those molecules to improve stability, selectivity, and delivery. The result could be an expanding range of peptide -based treatments addressing conditions far beyond weight management and hormone regulation. Inflammatory diseases are particularly interesting because they involve
complex communication networks between immune cells. And peptides are well -suited to participating in molecular signaling. That doesn't mean every inflammatory condition will eventually be treated with a peptide. But it does mean peptides may become increasingly important tools in immunology research. And icotide is a compelling example of that possibility. So, here's what I want you to take away from today's episode. On November 7th, 2026, Johnson & Johnson announced positive phase 3 clinical trial results involving Iketide,
an oral peptide medication already approved for plaque psoriasis. The study demonstrated improvements in joint disease activity among adults with active psoriatic arthritis, and it also demonstrated meaningful improvements in skin symptoms. The medication works by blocking the interleukin -23 receptor that interferes with an immune signaling pathway involved in inflammatory disease. Its oral delivery represents a significant achievement in peptide pharmaceutical development, but important
questions remain. Long -term effectiveness in psoriatic arthritis still requires continued evaluation. Additional safety information will accumulate as the medication is studied and used more broadly. And future research will help determine how it compares with established treatment options. The most exciting part of this story isn't simply that an oral peptide improved arthritis symptoms in a clinical trial. It's that we're seeing another example of carefully engineered peptide chemistry translating into real medical applications, and
that has implications for the future of the entire field. As scientists continue learning how to design more selective molecules and deliver them effectively, We may see additional peptide medications entering areas of medicine that once seemed difficult to reach. But that progress must continue to be guided by rigorous research. Because the goal isn't just to develop newer medications. It's to develop better treatments that meaningfully improve people's lives. And that requires more than promising headlines. It requires careful
clinical trials, transparent safety reporting, and an honest assessment of what the evidence actually demonstrates. For people living with chronic inflammatory diseases, additional scientifically validated treatment options could make an enormous difference. And for those of us fascinated by peptide science, developments like this remind us just how much potential remains to be explored. We're not just talking about peptides for weight loss. We're not just talking about peptides associated with recovery or longevity. We're talking about
a rapidly evolving area of pharmaceutical science with applications across multiple medical specialties. And that's why we'll continue following these developments right here on the peptide effect. Before we close, here's our final medical disclaimer. This episode is provided for educational and informational purposes only and does not constitute medical advice. Icotide, also known as icotrokinra, is FDA approved for certain patients with moderate to severe plaque psoriasis, but it is not currently
approved for treating active psoriatic arthritis. Its effectiveness and safety for that additional indication remain under clinical investigation. Like other medications that influence immune function, Iketide carries potential risks, including infections and other adverse reactions. Clinical trial results do not guarantee individual outcomes. Never start, stop, or change medications without consulting a qualified healthcare professional. Anyone experiencing persistent joint pain, swelling,
stiffness, or symptoms suggestive of inflammatory arthritis should seek an appropriate medical evaluation. And with that, we've reached the end of another episode of the Peptide Effect. From injectable medications to sophisticated oral peptide therapies, the world of peptide medicine continues to evolve. And discoveries like icotide remind us that peptides are much more than the research compounds we hear about in everyday conversations. They're becoming increasingly important tools in modern pharmaceutical development.
The future may bring new treatments, new delivery systems, and new approaches to diseases that have challenged researchers for decades. But as always, the science matters more than the hype. We'll continue following the clinical trials, the breakthroughs, and the emerging research that could shape the future of medicine. Because every new discovery gives us another opportunity to better understand the incredible complexity of the human body. And as always, thanks for listening, keep learning and stay curious.
Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode! 🧬🔥 RETATRUTIDE FOR CHRONIC PAIN? NEW RESEARCH REVEALS UP TO 75% REDUCTION IN KNEE ARTHRITIS PAIN! Could one of...
Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode! 🧬🔥 RETATRUTIDE VS. OZEMPIC: THE RESULTS ARE IN! Could the next generation of weight-loss peptides leave Ozempic...
Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode! 🧬 The Peptide Comeback: 6 Research Peptides Get a Regulatory Break - What You Need to Know Big news in the...
Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode! A Hollywood legend, two experimental peptides, and a fatal allergic reaction. In this episode of The Peptide...
Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode! Are weight-loss peptides a treat, or is the marketing playing tricks? 🎃 In this Halloween episode of The Peptide...